news2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about our scientific collaborations...A valuable ...
http://gwpharma.co.uk/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
PAGES IN
THIS WEBSITE
13
SSL
EXTERNAL LINKS
1
SITE IP
185.19.14.34
LOAD TIME
0 sec
SCORE
6.2
GWPharma - Welcome | gwpharma.co.uk Reviews
https://gwpharma.co.uk
news2Introducing GW PharmaceuticalsDiscover more about GW...Meeting patients' needsPatient information can be found here....World leading scienceMore about our scientific collaborations...A valuable ...
gwpharma.co.uk
GWPharma - Media
http://gwpharma.co.uk/media.aspx
Welcome to the media section of the GW website, dedicated to providing useful information for press enquiries. This section contains current and previous press releases, notes to editors, image library and media contact information. For a dedicated page relating to Sativex click here. GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress. London, UK, 9 August 2016: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, GW, the Company or the Gr.
GWPharma - Strategy
http://gwpharma.co.uk/gw-strategy.aspx
GW’s focus is to bring novel prescription medicines to market which provide patients with serious conditions with valuable medicines which make a real difference to their quality of life. Through rapid cost-effective product development, addressing market needs, and establishing commercial partnerships, GW seeks to maximise the value of its products and shareholder returns. GW seeks to enter into licence agreements with major pharmaceutical companies with a view to those companies undertaking the sales a...
GWPharma - Disclosure & Disclaimer
http://gwpharma.co.uk/Disclosure-and-Disclaimer.aspx
GW Pharmaceuticals plc is a public limited company incorporated and registered in England and Wales. Content and information provided by third parties other than the Company is identified clearly where it appears. The Company publishes this content as supplied to it and is not responsible for its accuracy or timeliness. You must take appropriate steps to verify this information before acting upon it. The information contained in this Website is not (and should not be construed as) a recommendation, invit...
GWPharma - Accessibility
http://gwpharma.co.uk/Accessibility.aspx
GW Pharmaceuticals recognise the importance of providing a website that is inclusive and available for all user groups. This page explains:. Our approach to making this website accessible;. The facilities that we have provided for different disability groups;. Guidance on how to use particular features;. What to do if you have any questions or feedback for us. Partially Sighted Users - Text size. Colour Blind Users - Colour. To select from dropdown boxes, use up and down arrow keys;. Complex images inclu...
GWPharma - Product Pipeline
http://gwpharma.co.uk/product-pipeline.aspx
GW Metabolic Research Laboratory. GW’s extensive research into the pharmacology of cannabinoids continues to yield highly promising data and new intellectual property across a range of therapeutic areas. GW continues to invest in research to accelerate further growth and value creation through the development and licensing of several new cannabinoid drug candidates.
TOTAL PAGES IN THIS WEBSITE
13
The domain www.gwpharm.biz is registered by NetNames
The domain name www.gwpharm.biz. Has been registered by NetNames. Every domain name comes with free web and email forwarding. To forward your domain name to another web page or site, log into your control panel at www.netnames.com. And change the web forwarding settings.
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
Home | GW Pharmaceuticals, plc
Skip to main content. We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK. Epilepsy Patients and Caregivers. GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs. Mar 15, 2018. Mar 05, 2018. Feb 27, 2018. GW Pharmaceuticals R...
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
The domain www.gwpharma.biz is registered by NetNames
The domain name www.gwpharma.biz. Has been registered by NetNames. Every domain name comes with free web and email forwarding. To forward your domain name to another web page or site, log into your control panel at www.netnames.com. And change the web forwarding settings.
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
The domain www.gwpharmaceuticals.biz is registered by NetNames
The domain name www.gwpharmaceuticals.biz. Has been registered by NetNames. Every domain name comes with free web and email forwarding. To forward your domain name to another web page or site, log into your control panel at www.netnames.com. And change the web forwarding settings.
GWPharma - Welcome
GW’s lead product, Sativex. Is approved in over 20 countries and the company has a highly promising pipeline of additional cannabinoid drug candidates in development. Discover more about GW. Sativex is approved to treat spasticity (muscle stiffness and spasm) due to Multiple Sclerosis, offering relief to patients for a condition that previously had limited treatment options. Patient information can be found here. More about our scientific collaborations. Our areas of therapeutic interest. GW Pharmaceutic...
